Latest Health News

OpenLearning Limited reported a 23% year-on-year increase in SaaS annual recurring revenue to $2.335 million in Q4 FY24, driven by strong growth in AI-powered products and strategic partnerships. The company also cut net operating cash outflows by over half, signaling improved operational efficiency.

Atomo Diagnostics reports a robust Q2 FY25 with $1.2 million revenue driven by HIV self-test sales and a significant $2.44 million government grant for syphilis test development. The company advances its market footprint in Australia and New Zealand while maintaining a strong cash position.

Visionflex Group reported an 8% increase in Annual Recurring Revenue to $1.6 million in Q2 FY25 despite an 11% revenue decline, securing key contracts with Spark Health, BUPA, and Indigenous Wellness Connect. The company targets EBITDA profitability by Q4 FY25 amid a maturing sales pipeline.

Mach7 Technologies has initiated a A$5 million on-market share buy-back program, reflecting confidence in its robust financial health and growth outlook. The move underscores the company’s commitment to capital management amid reaffirmed FY25 revenue growth guidance.

Lotus Resources has fast-tracked the restart of its Kayelekera uranium project in Malawi, targeting production by Q3 2025, backed by a $132 million capital raise. Meanwhile, its Letlhakane project in Botswana reports a 65% increase in measured and indicated uranium resources.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

BlueBet Holdings has delivered positive EBITDA for the first half of FY25 ahead of schedule, driven by strategic customer reactivation and enhanced platform efficiencies following its merger with betr.

Sovereign Metals has delivered an Optimised Prefeasibility Study reaffirming Kasiya’s status as a globally significant rutile and graphite project, alongside advancing rehabilitation efforts and positive graphite test results.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

Top End Energy Limited reported a net cash outflow in its December quarter, reducing its cash reserves to $2.76 million and leaving funding for just over two and a half quarters. The company’s cash flow dynamics highlight the ongoing financial pressures typical in early-stage oil and gas exploration.

Galileo Mining Ltd’s latest quarterly cash flow report reveals a $706,000 net cash decrease amid ongoing exploration spending, while maintaining a strong cash position of $11.3 million.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.